CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227. doi:10.1001/jamaoncol.2018.2128
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406. doi:10.3324/haematol.2015.129189
   PubMed Web of Science ®Google Scholar
• Romano A, Conticello C, Cavalli M, et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int. 2014;2014:198539. doi:10.1155/2014/198539
   PubMed Web of Science ®Google Scholar
• Costa F, Vescovini R, Marchica V, et al. PD-L1/PD-1 pattern of expression within the bone marrow immune microenvironment in smoldering myeloma and active multiple myeloma patients. Front Immunol. 2020;11:613007. doi:10.3389/fimmu.2020.613007
   PubMed Web of Science ®Google Scholar
• Häusler SF, Del Barrio IM, Diessner J, et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res. 2014;6(2):129–139.
   PubMed Web of Science ®Google Scholar
• Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA. 2013;110(27):11091–11096. doi:10.1073/pnas.1222251110
   PubMed Web of Science ®Google Scholar
• Lu XX, Chen YT, Feng B, et al. Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J Gastroenterol. 2013;19(12):1912–1918. doi:10.3748/wjg.v19.i12.1912
   PubMed Web of Science ®Google Scholar
• Wu XR, He XS, Chen YF, et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol. 2012;106(2):130–137. doi:10.1002/jso.23056
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Gaudreau PO, et al. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy. 2016;8(2):145–163. doi:10.2217/imt.15.106
   PubMed Web of Science ®Google Scholar
• Idzko M, Ferrari D, Riegel AK, et al. Extracellular nucleotide and nucleoside signaling in vascular and blood disease. Blood. 2014;124(7):1029–1037. doi:10.1182/blood-2013-09-402560
   PubMed Web of Science ®Google Scholar
• Ohta A, Ohta A, Madasu M, et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009;183(9):5487–5493. doi:10.4049/jimmunol.0901247
   PubMed Web of Science ®Google Scholar
• Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol. 2005;174(2):1073–1080. doi:10.4049/jimmunol.174.2.1073
   PubMed Web of Science ®Google Scholar
• Beavis PA, Stagg J, Darcy PK, et al. CD73: a potent suppressor of anti-tumor immune responses. Trends Immunol. 2012;33(5):231–237. doi:10.1016/j.it.2012.02.009
   PubMed Web of Science ®Google Scholar
• Zhu BD, Ren J, Wang XY, et al. Biological properties of mesenchymal stem cells derived from bone marrow of patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14(6):1138–1142.
   PubMedGoogle Scholar
• Yang R, Elsaadi S, Misund K, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020;8(1):e000610. doi:10.1136/jitc-2020-000610
   PubMed Web of Science ®Google Scholar
• Ray A, Song Y, Du T, et al. Identification and validation of ecto-5’ nucleotidase as an immunotherapeutic target in multiple myeloma. Blood Cancer J. 2022;12(4):50. doi:10.1038/s41408-022-00635-3
   PubMed Web of Science ®Google Scholar
• Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006;2(2):409–430. doi:10.1007/s11302-006-9003-5
   PubMedGoogle Scholar
• Azizi E, Carr AJ, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293–1308.e1236. doi:10.1016/j.cell.2018.05.060
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Skrzypczynska KM, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181(2):442–459.e429. doi:10.1016/j.cell.2020.03.048
   PubMed Web of Science ®Google Scholar
• Suen H, Brown R, Yang S, et al. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a Phase 1 study. Leukemia. 2015;29(7):1621–1622. doi:10.1038/leu.2015.104
   PubMed Web of Science ®Google Scholar
• Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21(20):4607–4618. doi:10.1158/1078-0432.CCR-15-0200
   PubMed Web of Science ®Google Scholar
• Pulte D, Furman RR, Broekman MJ, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(4):367–372. doi:10.1016/j.clml.2011.06.005
   PubMed Web of Science ®Google Scholar
• Lévesque J-P, Summers KM, Millard SM, et al. Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches. Exp Hematol. 2021;100:12–31.e11. doi:10.1016/j.exphem.2021.07.001
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014
   PubMed Web of Science ®Google Scholar
• Zhang Q, He Y, Luo N, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–845.e820. doi:10.1016/j.cell.2019.10.003
   PubMed Web of Science ®Google Scholar
• Bhattarai S, Freundlieb M, Pippel J, et al. α, β-Methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5’-nucleotidase (CD73) Inhibitors. J Med Chem. 2015;58(15):6248–6263. doi:10.1021/acs.jmedchem.5b00802
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626–5635. doi:10.1158/1078-0432.CCR-13-0545
   PubMed Web of Science ®Google Scholar